Physician profile
Kay Dee Roberts
NPI 1508057316
$11,643.31
in general payments reported to CMS, 2019-2025
46 companies · $1,962 in 2025
The $1,962 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,083 · 2022: $2,528 · 2023: $2,697 · 2024: $2,373 · 2025: $1,962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,032.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,407.26 | 2021-2025 | Ozempic, Rybelsus |
| Amgen INC. | $1,209.37 | 2021-2025 | Evenity, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $1,121.14 | 2021-2025 | Rexulti, Abilify Maintena |
| Lilly USA, LLC | $1,050.71 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $982.54 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $868.42 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $781.83 | 2021-2024 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $684.08 | 2021-2024 | Jardiance, Tradjenta, Synjardy |
| Abbvie INC. | $502.16 | 2021-2025 | |
| Lundbeck LLC | $380.52 | 2022-2025 | Rexulti |
| Dexcom, INC. | $298.45 | 2021-2025 | Dexcom G6 Transmitter |
| Nestle Healthcare Nutrition INC. | $207.10 | 2022-2023 | |
| Pfizer INC. | $201.31 | 2022-2025 | |
| Esperion Therapeutics, INC. | $185.81 | 2021-2023 | Nexletol |
| Novartis Pharmaceuticals Corporation | $184.84 | 2022-2023 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kay Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.